Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | HTR1A | P08908 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | HTR7 | P34969 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3379997 | 0.92 | CXCR4 (0.41) | HTR2AHTR1ADRD2HTR7HRH3 | |
| SCHEMBL3377402 | 0.91 | HTR2A (0.39) | HTR2AHTR1ADRD2HTR7HTR2C | |
| SCHEMBL3377710 | 0.91 | SOS1 (0.38) | HRH3CXCR4CACNA1BKDM4EALDH1A1 | |
| SCHEMBL3376778 | 0.90 | HTR2A (0.37) | HTR2ADRD2HTR7HTR2CHRH3 | |
| SCHEMBL3380056 | 0.90 | CXCR4 (0.45) | HTR2AHTR1ADRD2HTR7HRH3 | |
| SCHEMBL3376676 | 0.90 | SOS1 (0.43) | HRH3CXCR4KDM4EALDH1A1POLB | |
| SCHEMBL3376207 | 0.89 | CACNA1B (0.48) | CACNA1BCCR5KDM4EALDH1A1 | |
| SCHEMBL3377588 | 0.89 | KDM4E (0.36) | HTR2AHTR1ADRD2HTR7HRH3 | |
| SCHEMBL3377079 | 0.88 | HRH3 (0.34) | HTR2AHTR1ADRD2HTR7HRH3 | |
| SCHEMBL3379302 | 0.88 | CXCR4 (0.42) | HRH3CXCR4KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899296-B1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2010-11-17 | — | — | EP | claimed |
| US-7812040-B2 | such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders | PFIZER INC. (US) | 2010-10-12 | — | — | US | claimed |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2009-05-21 | — | — | US | claimed |
| EP-1899296-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2006136924-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-12-28 | — | — | WO | claimed |
| EP-1899296-B1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7812040-B2 | such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders | PFIZER INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2009-05-21 | — | — | US | disclosed |
| EP-1899296-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006136924-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | HRH3, HRH4, HRH2 | HTR2A 33/4885HTR1A 15/4885DRD2 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.